среда, 24 августа 2016 г.

AstraZeneca to sell molecule antibiotics business to Pfizer

AstraZeneca to sell molecule antibiotics business to Pfizer


Pharmaceutical company AstraZeneca plans to sell its molecule antibiotics business to Pfizer in a deal that will be valued in excess of $1.5 billion when rights, royalties and other payments are included. The sale marks a thawing of relations between the British company and New York-based Pfizer after an acrimonious battle to avoid a takeover just a few years ago.



from Biotech News